keyword
MENU ▼
Read by QxMD icon Read
search

Intravesical therapy

keyword
https://www.readbyqxmd.com/read/29770266/renal-granulomatosis-post-intravesical-bacillus-calmette-guerin-therapy-for-non-muscle-invasive-bladder-cancer
#1
Karen Tran-Harding, Rashmi T Nair, Halemane Ganesh
Intravesical Bacillus Calmette-Guerin (BCG) immunotherapy is a proven, effective treatment for intermediate- and high-risk non-muscle-invasive bladder cancer. Minor side effects are common and expected but systemic effects can occur in <5% of treated patients. We present a rare case of a 49-year-old male that presented with fever and chills after 3 weeks of intravesical BCG therapy post transurethral resection of bladder tumor. New renal lesions were present on contrast-enhanced computed tomography scan which was histologically proven to be necrotizing renal granulomatosis...
2018: Journal of Clinical Imaging Science
https://www.readbyqxmd.com/read/29761307/intravesical-bacillus-calmette-guerin-therapy-after-second-transurethral-resection-for-primary-t1-bladder-cancer
#2
Masato Baba, Susumu Kageyama, Tetsuya Yoshida, Ryo Fujiwara, Chul Jang Kim, Keita Takimoto, Masayuki Nagasawa, Hiroki Soga, Yukihiro Nagatani, Zenkai Nishikawa, Akihiro Kawauchi
BACKGROUND: To evaluate the effect of intravesical bacillus Calmette-Guerin (BCG) instillation therapy after second transurethral resection (TUR) on primary T1 bladder cancer. METHODS: The subjects were 180 patients diagnosed with T1 bladder cancer at our university and at affiliated hospitals between January 1990 and December 2015. Tumor residual rate, intravesical recurrence rate, and risk factors for intravesical recurrence were investigated. RESULTS: The median follow-up period was 26 (1-175) months...
May 14, 2018: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29749774/bladder-cancer-overview-and-disease-management-part-1-non-muscle-invasive-bladder-cancer
#3
Beverley Anderson
Part 1 of this two-part article provides an overview of bladder cancer and discusses its management. Since publication of a previous article entitled 'Understanding the role of smoking in the aetiology of bladder cancer' ( Anderson, 2009 ), the author has received many requests for an update. This article provides an overview of bladder cancer and its current management practices, underlining the continued role of smoking as the predominant risk factor in the disease's development. The management of bladder cancer is governed by specific guidelines...
May 10, 2018: British Journal of Nursing: BJN
https://www.readbyqxmd.com/read/29745935/-sequential-treatment-with-mitomycin-c-and-bcg-in-non-muscle-invasive-bladder-cancer
#4
Venancio Chantada-Abal, Cristina Chantada-Tirado, Leticia Lamas-Díaz, Francisco Caramés-Masana, Anselmo Damián Villegas-Piguave, Nuria Villar-Vázquez
Bacilus Calmette-Guerin (BCG) administered intravesical is an effective therapy in non muscle invasive bladder cancer (NMIBC), but it presents limitations regarding recurrence and toxicity. For years, many case series have been published where sequential therapy with BCG and Mitomycin C (MMC) was tried. In this article, we perform a review of the data supplied by these articles with the aim to determine the safety and efficacy of combination, and what is the group of patients it should be indicated. Many studies show that combination therapy did not cause more toxicity and improved the interval free of disease with decrease of tumor progression compared to BCG or MMC monotherapy...
May 2018: Archivos Españoles de Urología
https://www.readbyqxmd.com/read/29745931/-mitomycin-c-hivec-update-and-results-in-high-risk-patients
#5
Félix Guerrero-Ramos, Daniel Castellano-Gauna, Esther García-Rojo, José Manuel Duarte-Ojeda, Federico de la Rosa-Kehrmann, Felipe Villacampa-Aubá
Adjuvant endovesical treatment is a research field in constant exploration with the aim to minimize the risk of recurrence and progression of non muscle invasive bladder tumors. Over the last years, the administration of chemotherapy in a chemo hyperthermia regimen has been added to the existing regimens. There are various systems for its administration, but this article focus on HIVEC (Hyperthermic IntraVEsical Chemotherapy) and its current status. In this review article we update the results of this system in the case-scenarios it has been used (preoperative with ablative intention and as adjuvant therapy with prophylactic purposes), tolerance and security issues, on-going clinical trials and future perspectives...
May 2018: Archivos Españoles de Urología
https://www.readbyqxmd.com/read/29745929/-chemohyperthermia-using-mmc-in-non-muscle-invasive-bladder-cancer-current-status-and-future-perspectives
#6
Jacqueline J M J H Coenen, F Johannes P van Valenberg, Tom J H Arends, J Alfred Witjes
In an effort to decrease recurrence and progression rates in non-muscle-invasive bladder cancer (NMIBC), transurethral resection of a bladder tumor is followed by intravesical instillations using Mitomycin-C (MMC) and Bacillus Calmette-Guérin (BCG). In spite of these adjuvant treatment modalities, recurrence and progression rates remain high. Because of these limitations of current standard therapy and the shortage of BCG, there is a search for alternative forms of treatment in NMIBC. Intravesical MMC combined with hyperthermia, especially RF-induced QHT being most extensively investigated in the past 20 years, is one of these alternatives for intermediate- and high-risk NMIBC...
May 2018: Archivos Españoles de Urología
https://www.readbyqxmd.com/read/29745925/-mechanism-of-action-of-intravesical-bcg-biological-bases-and-clinical-applicability
#7
Joaquín A Carballido, María Rodríguez Monsalve
The therapeutic approaches developed around immune system modulation find the therapeutic contribution of intravesical Bacillus Calmette Guerin (BCG) for transitional cell bladder cancer an unquestionable example as a proof of concept of antitumor immunotherapy since more than 30 years ago. Intravesical immunotherapy for urothelial carcinomas is considered with periodic intravesical instillations schedules, and the one with longer historic development and wider diffusion is BCG in the form of suspension. BCG is a unique strain obtained from Mycobacterium bovis at the end of the first third of the XX century and represents the historically most successful immunotherapeutic modality of all tumors with a high level body of evidence...
May 2018: Archivos Españoles de Urología
https://www.readbyqxmd.com/read/29745922/-bcg-and-bladder-cancer-past-present-and-future
#8
Álvaro Sánchez González, Oscar Rodríguez Faba, Lucía Mosquera, Laia Sabiote, Alberto Breda, Joan Palou Redorta
BCG has been used in the treatment of NMIBC for more than 40 years. Nevertheless, its exact working mechanisms have not been completely discovered. Clinical and basic research done over all these years has generated much information but it could be summarized in a few simple statements. It has been demonstrated the best route of administration is intravesical, BCG is superior than intracavitary chemotherapy to prevent recurrence but its adverse events are worse. Recently, it has been demonstrated that BCG could delay or prevent progression to infiltrative cancer...
May 2018: Archivos Españoles de Urología
https://www.readbyqxmd.com/read/29740727/the-first-case-of-bacillus-calmette-gu%C3%A3-rin-induced-small-vessel-central-nervous-system-vasculitis
#9
REVIEW
Marc-Etienne Parent, Maxime Richer, Patrick Liang
To present an unrecognized vascular complication of bacillus Calmette-Guérin (BCG) therapy administered for superficial bladder carcinoma. We also review the potential mimickers for primary angiitis of the central nervous system (PACNS) as well as complications of intravesical BCG therapy. An 89-year-old Caucasian man with a history of relapsing high-grade bladder carcinoma treated with intravesical BCG presented with recurring episodes of right upper limb paresthesia with clumsiness and dysarthria. Magnetic resonance imaging of the head revealed multiple predominantly left-sided frontotemporal micronodular peri-vascular lesions...
May 9, 2018: Clinical Rheumatology
https://www.readbyqxmd.com/read/29737959/risk-factors-for-bladder-cancer-recurrence-survival-in-patients-with-upper-tract-urothelial-carcinoma
#10
Yu-Peng Wu, Yun-Zhi Lin, Min-Yi Lin, Ting-Ting Lin, Shao-Hao Chen, Yong Wei, Qing-Shui Zheng, Xue-Yi Xue, Ning Xu
Purpose The aim of this work was to investigate the predictive factors for bladder cancer recurrence survival (BCRS) in patients with upper-tract urothelial carcinoma (UTUC). Methods We selected patients with UTUC who underwent segmental ureterectomy (Su) or nephroureterectomy (Nu) from 2004 to 2013 from the Surveillance, Epidemiology, and End Results (SEER) database. Patients with a history of intravesical therapy for bladder cancer and bladder cancer prior to the diagnosis of UTUC were excluded. We used Kaplan-Meier analysis, log-rank tests, and Cox proportional hazards model to compare overall survival, cancer-specific survival, and BCRS...
December 1, 2017: Tumori
https://www.readbyqxmd.com/read/29730950/emerging-intravesical-drugs-for-the-treatment-of-non-muscle-invasive-bladder-cancer
#11
Jasper Crijnen, Theo M de Reijke
Bladder cancer (BC) is a severe health burden: it is the fifth most common malignancy in the world and has high recurrence and progression rates. Standard treatment starts with TURB followed by intravesical chemotherapy with Mitomycin C or immunotherapy with BCG. However, successful management still remains a challenge, because approximately 30% of patients have recurrence or progression within 5 years, and treatment has considerable side effects. Anticipating on the upcoming BCG shortage emphasizes, moreover, the necessity to develop and study novel treatments...
May 5, 2018: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/29721384/low-dose-gemcitabine-increases-the-cytotoxicity-of-human-v%C3%AE-9v%C3%AE-2-t-cells-in-bladder-cancer-cells-in-vitro-and-in-an-orthotopic-xenograft-model
#12
Teruki Shimizu, Mako Tomogane, Masatsugu Miyashita, Osamu Ukimura, Eishi Ashihara
Human γδT cell immunotherapy is well tolerated and has shown promising results in clinical trials; however, its antitumor efficacy is limited, including results in solid tumors. Ex-vivo expanded γδT cell stimulated by zoledronic acid (ZOL) activates the γδT cell subpopulation of so called Vγ9Vδ2 T cells. To improve the clinical outcomes of Vγ9Vδ2 T cell (abbreviated as γδT cell here) immunotherapy, we aimed to increase the cytotoxicity of γδT cells by focusing on two issues: recognition of tumor cells by γδT cells and the effector (γδT cell)-to-target (tumor cell) (E/T) ratio...
2018: Oncoimmunology
https://www.readbyqxmd.com/read/29702078/therapeutic-efficacy-of-the-live-attenuated-mycobacterium-tuberculosis-vaccine-mtbvac-in-a-preclinical-model-of-bladder-cancer
#13
Samuel Alvarez-Arguedas, Santiago Uranga, Manuel Martín, Javier Elizalde, Ana Belen Gomez, Esther Julián, Denise Nardelli-Haefliger, Carlos Martín, Nacho Aguilo
Intravesical instillation of bacillus Calmette-Guérin (BCG) has been a first-line therapy for non-muscle-invasive bladder cancer for the last 4 decades. However, this treatment causes serious adverse events in a significant number of patients and a substantial percentage of recurrence episodes. MTBVAC is a live-attenuated vaccine derived from a Mycobacterium tuberculosis clinical isolate and is currently under evaluation in clinical trials to replace BCG as a tuberculosis vaccine. Here, we describe for the first time the potential of MTBVAC as a bladder cancer therapy in vitro and in vivo in a preclinical model...
April 6, 2018: Translational Research: the Journal of Laboratory and Clinical Medicine
https://www.readbyqxmd.com/read/29696234/reduce-bladder-cancer-recurrence-in-patients-treated-for-upper-urinary-tract-urothelial-carcinoma-the-rebacare-trial
#14
T van Doeveren, P J van Leeuwen, K K H Aben, M van der Aa, M Barendrecht, E R Boevé, E B Cornel, A G van der Heijden, K Hendricksen, W Hirdes, A Kooistra, B Kroon, A M Leliveld, R P Meijer, H van Melick, B Merks, T M de Reijke, P de Vries, L F A Wymenga, B Wijsman, J L Boormans
Background: Following radical nephro-ureterectomy for urothelial carcinoma of the upper urinary tract (UUT), the reported bladder recurrence rate of urothelial carcinoma is 22-47%. A single intravesical instillation of chemotherapy within 10 days following nephro-ureterectomy has the potential to decrease the risk of a bladder recurrence significantly. Despite recommendation by the European Association of Urology guideline to administer a single instillation postoperatively, the compliance rate is low because the risk of extravasation of chemotherapy...
March 2018: Contemporary Clinical Trials Communications
https://www.readbyqxmd.com/read/29682358/acute-pericarditis-occurring-three-days-after-intravesical-instillation-of-mitomycin-c-after-transurethral-bladder-tumor-resection-in-a-64-year-old-woman
#15
Vineet Meghrajani, Arsalan Hashmi, Shuo Cheng Lin, Zvi Plawes, Shelly Brejt
We present a 64-year-old woman who developed symptoms of acute pericarditis three days after undergoing intravesical instillation of mitomycin C following transurethral bladder tumor resection. Mitomycin C is a chemotherapeutic agent which acts by alkylation of DNA and is known to be cardiotoxic when systemically administered. Despite classic pericarditis symptoms, the patient underwent an urgent coronary angiogram due to elevated cardiac troponin I level, EKG changes, and wall motion abnormalities on her echocardiogram...
2018: Case Reports in Cardiology
https://www.readbyqxmd.com/read/29679772/efficacy-of-cidofovir-in-treatment-of-bk-virus-induced-hemorrhagic-cystitis-in-post-allogeneic-hematopoietic-cell-transplant-recipients
#16
Eric A Coomes, Amanda Jacques Wolfe, Fotios V Michelis, Dennis Dong-Hwong Kim, Santhosh Thyagu, Auro Viswabandya, Jeffrey H Lipton, Hans A Messner, Uday Deotare
BACKGROUND: BK virus associated hemorrhagic cystitis (BK-HC) is a common complication after allogeneic hematopoietic stem cell transplantation (allo-HCT), with incidence up to 70%. Cidofovir is an antiviral agent with growing evidence as a therapeutic intervention. OBJECTIVE: To assess the safety profile and efficacy of intravenous and intravesical cidofovir in allo-HCT patients with BK-HC. METHODS: Retrospective study of the allo-HCT cohort who received cidofovir for symptomatic BK-HC (hematuria with BK viruria or viremia) from January 2010 until March 2017 in a single transplant center in Ontario, Canada...
April 18, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29676191/treatment-according-to-guidelines-may-bridge-the-gender-gap-in-outcome-for-patients-with-stage-t1-urinary-bladder-cancer
#17
Carin Sjöström, Andreas Thorstenson, Viveka Ströck, Abolfazl Hosseini-Aliabad, Firas Aljabery, Fredrik Liedberg, Amir Sherif, Per-Uno Malmström, Johan Rosell, Truls Gårdmark, Staffan Jahnson
OBJECTIVE: The aim of this investigation was to study differences between male and female patients with stage T1 urinary bladder cancer (UBC) regarding intravesical instillation therapy, second resection and survival. MATERIALS AND METHODS: This study included all patients with non-metastatic primary T1 UBC reported to the Swedish National Register of Urinary Bladder Cancer (SNRUBC) from 1997 to 2014, excluding those treated with primary cystectomy. Differences between groups were evaluated using chi-squared tests and logistic regression, and survival was investigated using Kaplan-Meier and log-rank tests and Cox proportional hazards analysis...
April 20, 2018: Scandinavian Journal of Urology
https://www.readbyqxmd.com/read/29643467/potential-orphan-drug-therapy-of-intravesical-liposomal-onabotulinumtoxin-a-for-ketamine-induced-cystitis-by-mucosal-protection-and-anti-inflammation-in-a-rat-model
#18
Wei-Chia Lee, Chia-Hao Su, You-Lin Tain, Cheng-Nan Tsai, Chun-Chieh Yu, Yao-Chi Chuang
Ketamine abusers may develop ulcerative cystitis and severe lower urinary tract symptoms, which is a medical dilemma. Recently, researchers have found the endemic of ketamine-induced cystitis worldwide. The intravesical administration of liposome-encapsulated onabotulinumtoxinA (Lipotoxin) might facilitate the healing of the damaged urothelium from liposomes, and reduce the urinary symptoms by onabotulinumtoxinA-induced chemo-denervation. Using female Sprague-Dawley rats, we investigated the effects of Lipotoxin on ketamine-induced cystitis...
April 11, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29642365/re-long-term-outcomes-of-intravesical-dimethyl-sulfoxide-heparin-hydrocortisone-therapy-for-interstitial-cystitis-bladder-pain-syndrome
#19
Alan J Wein
No abstract text is available yet for this article.
April 2018: Journal of Urology
https://www.readbyqxmd.com/read/29623107/intravesical-instillations-for-the-treatment-of-refractory-recurrent-urinary-tract-infections
#20
Sonia Dutta, Felicia Lane
Background: Treatment options for refractory recurrent urinary tract infections (UTI) are limited; therefore, we sought to determine if intravesical instillations with heparin effectively treat recurrent UTIs. Methods: Patients at an academic medical center who received intravesical instillations with heparin for recurrent UTIs/chronic cystitis between January 2011 and December 2015 were identified via International Classification of Diseases, Ninth Revision (ICD-9) and Current Procedural Terminology (CPT) procedure codes...
May 2018: Therapeutic Advances in Urology
keyword
keyword
21306
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"